Serum IgG and mucosal IgA antibodies from pre-pandemic samples collected in Kilifi, Kenya, neutralize SARS-CoV-2 in vitro
<strong>Objectives<br></strong> Many regions of Africa have experienced lower COVID-19 morbidity and mortality than Europe. Pre-existing humoral responses to endemic human coronaviruses (HCoV) may cross-protect against SARS-CoV-2. We investigated the neutralizing capacity of SARS-C...
| Váldodahkkit: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Materiálatiipa: | Journal article |
| Giella: | English |
| Almmustuhtton: |
Elsevier
2022
|
| _version_ | 1826310707085312000 |
|---|---|
| author | Nyagwange, J Kutima, B Mwai, K Karanja, HK Gitonga, JN Mugo, D Sein, Y Wright, D Omuoyo, DO Nyiro, JU Tuju, J Nokes, DJ Agweyu, A Bejon, P Ochola-Oyier, LI Scott, JAG Lambe, T Nduati, E Agoti, C Warimwe, GM |
| author_facet | Nyagwange, J Kutima, B Mwai, K Karanja, HK Gitonga, JN Mugo, D Sein, Y Wright, D Omuoyo, DO Nyiro, JU Tuju, J Nokes, DJ Agweyu, A Bejon, P Ochola-Oyier, LI Scott, JAG Lambe, T Nduati, E Agoti, C Warimwe, GM |
| author_sort | Nyagwange, J |
| collection | OXFORD |
| description | <strong>Objectives<br></strong>
Many regions of Africa have experienced lower COVID-19 morbidity and mortality than Europe. Pre-existing humoral responses to endemic human coronaviruses (HCoV) may cross-protect against SARS-CoV-2. We investigated the neutralizing capacity of SARS-CoV-2 spike reactive and nonreactive immunoglobulin (Ig)G and IgA antibodies in prepandemic samples.
<br><strong>Methods<br></strong>
To investigate the presence of pre-existing immunity, we performed enzyme-linked immunosorbent assay using spike antigens from reference SARS-CoV-2, HCoV HKU1, OC43, NL63, and 229E using prepandemic samples from Kilifi in coastal Kenya. In addition, we performed neutralization assays using pseudotyped reference SARS-CoV-2 to determine the functionality of the identified reactive antibodies.
<br><strong>Results<br></strong>
We demonstrate the presence of HCoV serum IgG and mucosal IgA antibodies, which cross-react with the SARS-CoV-2 spike. We show pseudotyped reference SARS-CoV-2 neutralization by prepandemic serum, with a mean infective dose 50 of 1: 251, which is 10-fold less than that of the pooled convalescent sera from patients with COVID-19 but still within predicted protection levels. The prepandemic naso-oropharyngeal fluid neutralized pseudo-SARS-CoV-2 at a mean infective dose 50 of 1: 5.9 in the neutralization assay.
<br><strong>Conclusion<br></strong>
Our data provide evidence for pre-existing functional humoral responses to SARS-CoV-2 in Kilifi, coastal Kenya and adds to data showing pre-existing immunity for COVID-19 from other regions. |
| first_indexed | 2024-03-07T07:55:58Z |
| format | Journal article |
| id | oxford-uuid:620bb9af-16e2-4e6f-aa52-db81b200f038 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:55:58Z |
| publishDate | 2022 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:620bb9af-16e2-4e6f-aa52-db81b200f0382023-08-17T11:36:11ZSerum IgG and mucosal IgA antibodies from pre-pandemic samples collected in Kilifi, Kenya, neutralize SARS-CoV-2 in vitroJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:620bb9af-16e2-4e6f-aa52-db81b200f038EnglishSymplectic ElementsElsevier2022Nyagwange, JKutima, BMwai, KKaranja, HKGitonga, JNMugo, DSein, YWright, DOmuoyo, DONyiro, JUTuju, JNokes, DJAgweyu, ABejon, POchola-Oyier, LIScott, JAGLambe, TNduati, EAgoti, CWarimwe, GM<strong>Objectives<br></strong> Many regions of Africa have experienced lower COVID-19 morbidity and mortality than Europe. Pre-existing humoral responses to endemic human coronaviruses (HCoV) may cross-protect against SARS-CoV-2. We investigated the neutralizing capacity of SARS-CoV-2 spike reactive and nonreactive immunoglobulin (Ig)G and IgA antibodies in prepandemic samples. <br><strong>Methods<br></strong> To investigate the presence of pre-existing immunity, we performed enzyme-linked immunosorbent assay using spike antigens from reference SARS-CoV-2, HCoV HKU1, OC43, NL63, and 229E using prepandemic samples from Kilifi in coastal Kenya. In addition, we performed neutralization assays using pseudotyped reference SARS-CoV-2 to determine the functionality of the identified reactive antibodies. <br><strong>Results<br></strong> We demonstrate the presence of HCoV serum IgG and mucosal IgA antibodies, which cross-react with the SARS-CoV-2 spike. We show pseudotyped reference SARS-CoV-2 neutralization by prepandemic serum, with a mean infective dose 50 of 1: 251, which is 10-fold less than that of the pooled convalescent sera from patients with COVID-19 but still within predicted protection levels. The prepandemic naso-oropharyngeal fluid neutralized pseudo-SARS-CoV-2 at a mean infective dose 50 of 1: 5.9 in the neutralization assay. <br><strong>Conclusion<br></strong> Our data provide evidence for pre-existing functional humoral responses to SARS-CoV-2 in Kilifi, coastal Kenya and adds to data showing pre-existing immunity for COVID-19 from other regions. |
| spellingShingle | Nyagwange, J Kutima, B Mwai, K Karanja, HK Gitonga, JN Mugo, D Sein, Y Wright, D Omuoyo, DO Nyiro, JU Tuju, J Nokes, DJ Agweyu, A Bejon, P Ochola-Oyier, LI Scott, JAG Lambe, T Nduati, E Agoti, C Warimwe, GM Serum IgG and mucosal IgA antibodies from pre-pandemic samples collected in Kilifi, Kenya, neutralize SARS-CoV-2 in vitro |
| title | Serum IgG and mucosal IgA antibodies from pre-pandemic samples collected in Kilifi, Kenya, neutralize SARS-CoV-2 in vitro |
| title_full | Serum IgG and mucosal IgA antibodies from pre-pandemic samples collected in Kilifi, Kenya, neutralize SARS-CoV-2 in vitro |
| title_fullStr | Serum IgG and mucosal IgA antibodies from pre-pandemic samples collected in Kilifi, Kenya, neutralize SARS-CoV-2 in vitro |
| title_full_unstemmed | Serum IgG and mucosal IgA antibodies from pre-pandemic samples collected in Kilifi, Kenya, neutralize SARS-CoV-2 in vitro |
| title_short | Serum IgG and mucosal IgA antibodies from pre-pandemic samples collected in Kilifi, Kenya, neutralize SARS-CoV-2 in vitro |
| title_sort | serum igg and mucosal iga antibodies from pre pandemic samples collected in kilifi kenya neutralize sars cov 2 in vitro |
| work_keys_str_mv | AT nyagwangej serumiggandmucosaligaantibodiesfromprepandemicsamplescollectedinkilifikenyaneutralizesarscov2invitro AT kutimab serumiggandmucosaligaantibodiesfromprepandemicsamplescollectedinkilifikenyaneutralizesarscov2invitro AT mwaik serumiggandmucosaligaantibodiesfromprepandemicsamplescollectedinkilifikenyaneutralizesarscov2invitro AT karanjahk serumiggandmucosaligaantibodiesfromprepandemicsamplescollectedinkilifikenyaneutralizesarscov2invitro AT gitongajn serumiggandmucosaligaantibodiesfromprepandemicsamplescollectedinkilifikenyaneutralizesarscov2invitro AT mugod serumiggandmucosaligaantibodiesfromprepandemicsamplescollectedinkilifikenyaneutralizesarscov2invitro AT seiny serumiggandmucosaligaantibodiesfromprepandemicsamplescollectedinkilifikenyaneutralizesarscov2invitro AT wrightd serumiggandmucosaligaantibodiesfromprepandemicsamplescollectedinkilifikenyaneutralizesarscov2invitro AT omuoyodo serumiggandmucosaligaantibodiesfromprepandemicsamplescollectedinkilifikenyaneutralizesarscov2invitro AT nyiroju serumiggandmucosaligaantibodiesfromprepandemicsamplescollectedinkilifikenyaneutralizesarscov2invitro AT tujuj serumiggandmucosaligaantibodiesfromprepandemicsamplescollectedinkilifikenyaneutralizesarscov2invitro AT nokesdj serumiggandmucosaligaantibodiesfromprepandemicsamplescollectedinkilifikenyaneutralizesarscov2invitro AT agweyua serumiggandmucosaligaantibodiesfromprepandemicsamplescollectedinkilifikenyaneutralizesarscov2invitro AT bejonp serumiggandmucosaligaantibodiesfromprepandemicsamplescollectedinkilifikenyaneutralizesarscov2invitro AT ocholaoyierli serumiggandmucosaligaantibodiesfromprepandemicsamplescollectedinkilifikenyaneutralizesarscov2invitro AT scottjag serumiggandmucosaligaantibodiesfromprepandemicsamplescollectedinkilifikenyaneutralizesarscov2invitro AT lambet serumiggandmucosaligaantibodiesfromprepandemicsamplescollectedinkilifikenyaneutralizesarscov2invitro AT nduatie serumiggandmucosaligaantibodiesfromprepandemicsamplescollectedinkilifikenyaneutralizesarscov2invitro AT agotic serumiggandmucosaligaantibodiesfromprepandemicsamplescollectedinkilifikenyaneutralizesarscov2invitro AT warimwegm serumiggandmucosaligaantibodiesfromprepandemicsamplescollectedinkilifikenyaneutralizesarscov2invitro |